Patient, Provider, and Caregiver Connection™: Collaborative Approaches to Chronic Kidney Disease Management in T2DM

Released On
October 11, 2021

Expires On
October 11, 2022

Media Type
Internet

Completion Time
90 minutes

Specialty
Cardiology, Endocrinology, Nephrology, Primary Care

Topic(s)
Diabetes, Heart, Heart Disease, Kidney Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward nephrologists, cardiologists, primary care clinicians, nurse practitioners, and physician assistants, and other health care professionals involved in the management of patients with CKD.

Program Overview

This video-based program is designed for health care professionals to explore the available treatments for diabetic kidney disease (DKD) through a unique perspective, putting the patient’s voice front and center. A patient will lend their expertise to this program by sharing their journey living with DKD. This online activity focuses on the complex disease pathophysiology of DKD, the diseases and complications directly related to DKD, and the efficacy and safety of therapies recommended for treating DKD.

Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke and cardiac and vascular disease. Patients with DKD have a high risk of renal and diabetes complications, including diabetic retinopathy, diabetic foot, anemia, metabolic bone disease, fractures, infection, and neuropathy. Not surprisingly, this burden of complications and comorbidities translates to poor quality of life and substantially higher healthcare resource utilization and costs. Effective treatment for DKD is a key unmet need because, although advances in diabetes care have substantially reduced the incidence of most diabetes complications, efforts to reduce progression to end-stage renal disease (ESRD) have stubbornly lagged behind others. There are several classes of glucose-lowering drugs that have shown beneficial renal effects in patients with DKD. These include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and nonsteroidal mineralocorticoid receptor antagonists (MRAs).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe recommended diagnostic practices for CKD in patients with type 2 diabetes mellitus (T2DM)
  • Evaluate the efficacy and safety profiles of available antihyperglycemic agents and their cardiovascular and renal benefits in patients with T2DM
  • Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression

Faculty

FACULTY_NAME

George Bakris, MD

Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

FACULTY_NAME

Kim Zuber, PAC, MS

Executive Director
American Academy of Nephrology PAs
St Petersburg, FL

Patient

Janice Starling
Patient with CKD

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

George Bakris, MD

  • Consultant: Merck, Bayer, Vascular Dynamics, KBP Biosciences, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Quantum Genomics, Horizon Therapeutics, Novo Nordisk

Kim Zuber, PAC, MS, has no relevant financial relationships with ineligible companies.

Janice Starling (Patient), has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.